Clinica Universidad De Navarra — Sponsor Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

6 Recruiting

2 Completed trials

2 Countries active

13 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase III/IV

Phase IV

Phase II: 4 Phase I/II: 2 Phase III/IV: 1 Phase IV: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Actinic keratosis 1 Brain neoplasm malignant 1

Top IMPs

CAPECITABINE 1 LIDOCAINE HYDROCHLORIDE 1 MAGNESIUM SULFATE HEPTAHYDRATE 1 OXALIPLATIN 1 SODIUM CHLORIDE 1 TASADENOTUREV 1 TIRBANIBULIN 1 TOLCAPONE 1 TRANSPOCART19 1

All trials

8 total

INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS Recruiting

2024-515009-24-00 Phase II 2 countries TASADENOTUREV
Randomized and controlled clinical trial of the efficacy and safety of the use of lidocaine and magnesium sulfate for lung resection surgery… Recruiting

2023-509503-33-00 Phase IV 1 country LIDOCAINE HYDROCHLORIDE; MAGNESIUM SULFATE HEPTAHYDRATE; SODIUM CHLORIDE
Single-center phase I/IIa study with CART cells produced using the anti-CD19 transposon technique (TranspoCART19) for patients with CD19+ ac… Recruiting

2025-522673-11-00 Phase I/II 1 country TRANSPOCART19
Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line trea… Recruiting

2024-511459-16-00 Phase I/II 1 country
ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER. Recruiting

2024-519825-39-00 Phase II 1 country CAPECITABINE; OXALIPLATIN
Novel treatment with botulinum toxin for erectile dysfunction unresponsive to conventional treatment Recruiting

2024-514518-10-00 Phase II 1 country
Clinical efficacy and safety of sequential therapy with cryotherapy and topical tirbanibulin 1% in actinic keratoses in transplant recipient… Ended

2023-508091-11-00 Phase III/IV 1 country TIRBANIBULIN
EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680 Ended

2024-511433-35-00 Phase II 1 country TOLCAPONE

Showing 1–8 of 8 trials

← All sponsors A–Z